Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 136 AL 150

scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease

Ma K, Thomason LA, McLaurin J.

Adv Pharmacol. 2012;64:177-212. doi: 10.1016/B978-0-12-394816-8.00006-4.

Beyond amyloid: the future of therapeutics for Alzheimer's disease

Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM.

Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6.

Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease

Xu J, Kurup P, Nairn AC, Lombroso PJ.

Adv Pharmacol. 2012;64:303-25. doi: 10.1016/B978-0-12-394816-8.00009-X.

Tamibarotene: a candidate retinoid drug for Alzheimer's disease

Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K.

Biol Pharm Bull. 2012;35(8):1206-12. doi: 10.1248/bpb.b12-00314.

Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress

Kim HA, Miller AA, Drummond GR, Thrift AG, Arumugam TV, Phan TG, Srikanth VK, Sobey CG.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):953-9. doi: 10.1007/s00210-012-0790-7. Epub 2012 Aug 8.

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics

Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA.

J Alzheimers Dis. 2012;32(4):905-18. doi: 10.3233/JAD-2012-121075.

Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Teich AF, Arancio O.

Biochem J. 2012 Sep 1;446(2):165-77. doi: 10.1042/BJ20120653.

Naturally occurring autoantibodies against β-Amyloid

Bach JP, Dodel R.

Adv Exp Med Biol. 2012;750:91-9. doi: 10.1007/978-1-4614-3461-0_7.

[Gamma-secretase inhibitors in Alzheimer's disease therapy]

Katarína S, Jan K, Kamil K, Kamil M.

Ceska Slov Farm. 2012 Jun;61(3):93-100.

Targeting synaptic dysfunction in Alzheimer's disease therapy

Nisticò R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G.

Mol Neurobiol. 2012 Dec;46(3):572-87. doi: 10.1007/s12035-012-8324-3. Epub 2012 Aug 23.

The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study

Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF.

Am J Geriatr Pharmacother. 2012 Oct;10(5):296-302. doi: 10.1016/j.amjopharm.2012.08.002. Epub 2012 Aug 22.

Natural products as a rich source of tau-targeting drugs for Alzheimer's disease

Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ.

Future Med Chem. 2012 Sep;4(13):1751-61. doi: 10.4155/fmc.12.124.

BACE1 in Alzheimer's disease

Sathya M, Premkumar P, Karthick C, Moorthi P, Jayachandran KS, Anusuyadevi M.

Clin Chim Acta. 2012 Dec 24;414:171-8. doi: 10.1016/j.cca.2012.08.013. Epub 2012 Aug 20.

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease

Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J.

Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):421-32. doi: 10.1177/1533317512454708.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias